Intravitreal CBD-loaded niosomes enhance retinal neuroprotection in ischemic injury

IF 4.4 2区医学 Q1 PHARMACOLOGY & PHARMACY

European Journal of Pharmaceutics and Biopharmaceutics Pub Date : 2025-03-31 DOI:10.1016/j.ejpb.2025.114705

Carolina Nunes Silva , Lays Fernanda Nunes Dourado , Bárbara Leão Agata , Maísa Angélica Silva Fernandes , Marina França Dias , Sílvia Ligorio Fialho

{"title":"Intravitreal CBD-loaded niosomes enhance retinal neuroprotection in ischemic injury","authors":"Carolina Nunes Silva , Lays Fernanda Nunes Dourado , Bárbara Leão Agata , Maísa Angélica Silva Fernandes , Marina França Dias , Sílvia Ligorio Fialho","doi":"10.1016/j.ejpb.2025.114705","DOIUrl":null,"url":null,"abstract":"<div><div>Cannabidiol (CBD) has emerged as a promising treatment for conditions like retinal ischemia, characterized by reduced blood flow to the retina and significant vision loss. Despite its therapeutic potential, CBD’s clinical application could be limited by due to its low bioavailability. This study investigates the efficacy of CBD-loaded niosomes as a neuroprotective formulation for the use in ocular therapies related to retinal ischemia. We investigated the neuroprotective effects of CBD using a nanodispersed system (niosomes) administered via intravitreal injection in rats’ eyes. Niosomes underwent characterization for size, distribution, zeta potential, morphology, and encapsulation efficiency. Safety and neuroprotective activity were assessed by electroretinography (ERG), confocal and transmission microscopy and histology. Niosomes exhibited nanometric size (100–400 nm) and stability, showing good tolerance in animals. ERG results demonstrated higher b-wave amplitudes in animals pre-treated with niosomes + CBD compared to the control group following ischemic injury induced by a sudden increase in IOP. Histological and confocal microscopy analyses of retinas from the niosomes + CBD group showed preserved structure compared to the ischemic control group, suggesting significant retinal protection by intravitreally injected niosomes + CBD before ischemia. CBD-loaded niosomes effectively preserved retinal function, highlighting the neuroprotective potential of CBD against retinal ischemia. This formulation presents a promising and innovative treatment for ischemic retinal diseases.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"211 ","pages":"Article 114705"},"PeriodicalIF":4.4000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125000827","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Cannabidiol (CBD) has emerged as a promising treatment for conditions like retinal ischemia, characterized by reduced blood flow to the retina and significant vision loss. Despite its therapeutic potential, CBD’s clinical application could be limited by due to its low bioavailability. This study investigates the efficacy of CBD-loaded niosomes as a neuroprotective formulation for the use in ocular therapies related to retinal ischemia. We investigated the neuroprotective effects of CBD using a nanodispersed system (niosomes) administered via intravitreal injection in rats’ eyes. Niosomes underwent characterization for size, distribution, zeta potential, morphology, and encapsulation efficiency. Safety and neuroprotective activity were assessed by electroretinography (ERG), confocal and transmission microscopy and histology. Niosomes exhibited nanometric size (100–400 nm) and stability, showing good tolerance in animals. ERG results demonstrated higher b-wave amplitudes in animals pre-treated with niosomes + CBD compared to the control group following ischemic injury induced by a sudden increase in IOP. Histological and confocal microscopy analyses of retinas from the niosomes + CBD group showed preserved structure compared to the ischemic control group, suggesting significant retinal protection by intravitreally injected niosomes + CBD before ischemia. CBD-loaded niosomes effectively preserved retinal function, highlighting the neuroprotective potential of CBD against retinal ischemia. This formulation presents a promising and innovative treatment for ischemic retinal diseases.

Abstract Image

查看原文本刊更多论文

玻璃体内负载cbd的niosomes增强缺血性损伤视网膜神经保护作用

大麻二酚（CBD）已经成为一种有希望的治疗视网膜缺血等疾病的方法，其特征是视网膜血流量减少和严重的视力丧失。尽管CBD具有治疗潜力，但由于其生物利用度低，其临床应用可能受到限制。本研究探讨了cbd负载niosomes作为一种神经保护制剂用于视网膜缺血相关的眼部治疗的功效。我们使用纳米分散系统（niosomes）通过大鼠眼玻璃体内注射来研究CBD的神经保护作用。研究人员对Niosomes的大小、分布、zeta电位、形态和包封效率进行了表征。通过视网膜电图（ERG）、共聚焦显微镜和透射显微镜以及组织学评估其安全性和神经保护活性。纳米粒具有纳米尺寸（100-400 nm）和稳定性，在动物中表现出良好的耐受性。ERG结果显示，在IOP突然升高引起的缺血性损伤后，与对照组相比，经niosomes + CBD预处理的动物的b波振幅更高。与缺血对照组相比，乳小体+ CBD组视网膜的组织学和共聚焦显微镜分析显示，与缺血对照组相比，乳小体+ CBD组的视网膜结构得到了保留，这表明在缺血前玻璃体内注射乳小体+ CBD对视网膜有明显的保护作用。负载CBD的神经小体有效地保护了视网膜功能，突出了CBD对视网膜缺血的神经保护潜力。这个配方提出了一个有前途的和创新的治疗缺血性视网膜疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Pharmaceutics and Biopharmaceutics 医学-药学

CiteScore

8.80

自引率

4.10%

发文量

211

审稿时长

36 days

期刊介绍： The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics. Topics covered include for example: Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids) Aspects of manufacturing process design Biomedical aspects of drug product design Strategies and formulations for controlled drug transport across biological barriers Physicochemical aspects of drug product development Novel excipients for drug product design Drug delivery and controlled release systems for systemic and local applications Nanomaterials for therapeutic and diagnostic purposes Advanced therapy medicinal products Medical devices supporting a distinct pharmacological effect.